Encapsulation of Flavonoids in Nanocarriers

2022 ◽  
pp. 267-283
Author(s):  
Ashfaq Ahmad Shah ◽  
Amit Gupta

The term “flavonoid” is a broad term given to the collection of natural polyphenolic compounds which occur in plants (fruits, vegetables, roots, flowers, stems, bark, leaves) as their secondary metabolites. Subsequent research reveals that flavonoids possess anti-inflammatory, anti-mutagenic, anti-oxidative, anti-ageing, and anti-carcinogenic effects along with their capacity to modulate enzymatic activities, inhibit cell proliferation, and inhibit bacterial growth, among others. The main shortcomings of oral administration of flavonoids as therapeutic that various studies have revealed are related to their stability, bioefficacy, and bioavailability. Novel nanotechnological strategies involving nanocarrier systems are proving promising to overcome the delivery challenge of flavonoids as therapeutics. Nanocapsules, nanospheres, solid lipid nanoparticles, nanoemulsions, micelles are examples of novel nanocarrier systems that are currently being explored for targeted and efficient bio functioning of flavonoids after their oral administration.

2020 ◽  
Vol 17 (4) ◽  
pp. 343-347
Author(s):  
Harinder Singh ◽  
Ruchi Sood ◽  
Tridib Chaira ◽  
Alka Khanna ◽  
Dilip J Upadhaya ◽  
...  

Background: Rifampicin is known to degrade at the acidic pH of the stomach, especially in the presence of isoniazid. Although isoniazid also degrades partially, its degradation is reversible. Objective: Presently, we provide a proof of the fact that the simultaneous oral administration of rifampicin (RIF), upon incorporation into solid lipid nanoparticles (RIF-SLNs), with isoniazid (INH) overcomes its INH-induced degradation and improves its oral bioavailability in rats. Methods: Solid lipid nanoparticles of RIF (RIF-SLNs) were prepared using a novel and patented method. The effect of INH was investigated on in vivo bioavailability of RIF both in its free and encapsulated (RIF-SLNs) form, after oral administration to rats. Results: Cmax and AUC0-∞ of RIF increased 158 % and 125 %, respectively, upon incorporation into SLNs versus free RIF when combined with INH. The Tmax decreased from 5.67 h to 3.3 h, and the plasma concentration of RIF remained above its MIC (8 μg/ml) at all the tested time points starting with 15 min, when administered as RIF-SLNs in combination with INH. Conclusions: The results confirm the scope of combining RIF-SLNs with INH to overcome the bioavailability of free RIF when combined with INH, especially in fixed dose combinations.


2012 ◽  
pp. 3333 ◽  
Author(s):  
Huixia Lv Hui-Xia ◽  
Zhen-Hai Zhang ◽  
Yin-long Zhang ◽  
Xu Wang ◽  
Xi-Ru Xu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document